Literature DB >> 13722334

Peripheral neuritis due to isoniazid.

S DEVADATTA, P R GANGADHARAM, R H ANDREWS, W FOX, C V RAMAKRISHNAN, J B SELKON, S VELU.   

Abstract

It is well known that in the treatment of tuberculosis with isoniazid the complication of peripheral neuritis may arise. This complication is normally rare when small dosages of the drug are used, but a high incidence of the neuropathy has recently been observed in East Africa in a group of malnourished tuberculous patients receiving isoniazid in comparatively low dosage (4-6 mg/kg body-weight daily). The present paper reports on 20 cases of peripheral neuritis encountered in Madras, India, among 338 poorly nourished tuberculous patients during a trial of four isoniazid regimens, two of low and two of high dosage (3.9-5.5 and 7.8-9.6 mg/kg body-weight daily, respectively). Nineteen of the 20 cases occurred in the two groups of patients receiving the high dosage and these 19 patients were found to have a higher mean serum level of free isoniazid than the patients in the same groups who did not develop the complication. The authors consider that dosages of 7.8-9.6 mg/kg body-weight daily should not be used for the mass therapy of poorly nourished patients unless steps are taken to prevent the development of peripheral neuritis. Pyridoxine has been reported to be an effective preventive, but is too expensive for use on a large scale. This study indicates, however, that administration of the cheaper vitamin B complex might give satisfactory results and warrants further investigation.

Entities:  

Keywords:  ISONIAZID/toxicology; NEURITIS/etiology; PERIPHERAL NERVES/diseases

Mesh:

Substances:

Year:  1960        PMID: 13722334      PMCID: PMC2555613     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  15 in total

1.  Large dose isoniazid regimen for pulmonary tuberculosis; effect of glutamic acid; management of drug toxicity with pyridoxine.

Authors:  C ADAMSON; S IKARD; I TCHERTKOFF; R YILMAZ
Journal:  Sea View Hosp Bull       Date:  1956-07

2.  The relationship of neuropathy to the treatment of tuberculosis with isoniazid.

Authors:  G J DIXON; G B ROBERTS; W F TYRRELL
Journal:  Scott Med J       Date:  1956-11       Impact factor: 0.729

3.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

Authors:  H B HUGHES; J P BIEHL; A P JONES; L H SCHMIDT
Journal:  Am Rev Tuberc       Date:  1954-08

4.  Effect of isoniazid on vitamin B6 metabolism; its possible significance in producing isoniazid neuritis.

Authors:  J P BIEHL; R W VILTER
Journal:  Proc Soc Exp Biol Med       Date:  1954-03

5.  Toxicity of isoniazid.

Authors:  J P BIEHL; J H SKLAVEM
Journal:  Am Rev Tuberc       Date:  1953-08

6.  Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin; para-aminosalicylic acid in pulmonary tuberculosis therapy. IV. Report on forty-week observations on 583 patients with streptomycin susceptible infections.

Authors:  F W MOUNT; B E JENKINS; S H FEREBEE
Journal:  Am Rev Tuberc       Date:  1953-08

7.  The effect of vitamin B6 deficiency induced by desoxypyridoxine in human beings.

Authors:  R W VILTER; J F MUELLER; H S GLAZER; T JARROLD; J ABRAHAM; C THOMPSON; V R HAWKINS
Journal:  J Lab Clin Med       Date:  1953-09

8.  Peripheral neuropathy due to isoniazid; report of two cases.

Authors:  W A JONES; G P JONES
Journal:  Lancet       Date:  1953-05-30       Impact factor: 79.321

9.  Peripheral neuritis due to hydrazide derivatives.

Authors:  S KATZ; R GRUVER; B SMITH; G McCORMICK
Journal:  Dis Chest       Date:  1954-09

10.  Neural toxicity in tuberculous patients treated with isoniazid (isonicotinic acid hydrazide).

Authors:  G C GAMMON; F W BURGE; G KING
Journal:  AMA Arch Neurol Psychiatry       Date:  1953-07
View more
  53 in total

1.  MULTIPLE DEFICIENCY STATE ASSOCIATED WITH ISONIAZID THERAPY.

Authors:  D L ASPINALL
Journal:  Br Med J       Date:  1964-11-07

2.  ENZYMES AND DRUG SENSITIVITY. ACETYLATION POLYMORPHISMS.

Authors:  D A EVANS
Journal:  Proc R Soc Med       Date:  1964-06

3.  Diathesis and disease. The Osler oration, 1963.

Authors: 
Journal:  Can Med Assoc J       Date:  1963-07-06       Impact factor: 8.262

4.  REALISTIC CHEMOTHERAPEUTIC POLICIES FOR TUBERCULOSIS IN THE DEVELOPING COUNTRIES.

Authors:  W FOX
Journal:  Br Med J       Date:  1964-01-18

5.  Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.

Authors:  S VELU; R H ANDREWS; J H ANGEL; S DEVADATTA; W FOX; P R GANGADHARAM; A S NARAYANA; C V RAMAKRISHNAN; J B SELKON; P R SOMASUNDARAM
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

6.  The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS.

Authors:  C V RAMAKRISHNAN; A L BHATIA; S DEVADATTA; W FOX; A S NARAYANA; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

Review 7.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

8.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

9.  Blood protein conjugates and acetylation of aromatic amines. New findings on biological monitoring.

Authors:  J Lewalter; U Korallus
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

10.  Antinuclear antibodies during procainamide treatment and drug acetylation.

Authors:  D M Davies; M A Beedie; M D Rawlins
Journal:  Br Med J       Date:  1975-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.